



# RADx Data Hub: Study Registration Processes




***Vivian OTA WANG, Ph.D., CGC, FACMG***

*Deputy Director, Office of Data Sharing  
Center for Biomedical Informatics &  
Information Technology (CBIIT)  
National Cancer Institute-NIH  
3 February, 2021*

# RADx RAD Data Management Overview



# RADx RAD Data Management Overview



## WHO

- RESEARCH PARTICIPANTS PROTECTIONS

## WHAT

- RESEARCH PARTICIPANT PROTECTIONS
- BROAD DATA SHARING

## HOW

- STUDY REGISTRATION
  - INSTITUTIONAL CERTIFICATION
  - DATA SHARING/ SUBMISSION INFORMATION

# INSTITUTIONAL CERTIFICATION

OMB Control Number: 0925-0670  
Expiration Date: November 30, 2022  
[Clear Form](#)

Rapid Acceleration for Diagnostics Program (RADx) Institutional Certification\*

For studies using data generated for the Rapid Acceleration of Diagnostics Program (RADx)

Date: 02/02/2021

Name of RADx Program Admin:

NIH, HHS 9000 Rockville Pike Bethesda, MD 20892-7395

Re: Institutional Certification of [NAME OF INSTITUTION] to Accompany Submission of the Dataset from [ORIGINAL STUDY NAME] for [PROJECT TITLE FOR DATA TO BE SUBMITTED] to an NIH-designated data repository.

Dear \_\_\_\_\_  
The submission of data to the NIH-designated data repository is being made with institutional approval from \_\_\_\_\_, along with appropriate institutional approvals from \_\_\_\_\_, as listed here:

[IF APPLICABLE ENTER COLLABORATING SITE NAMES HERE AND CLICK 'ADD TO LIST'] [LIST OF COLLABORATING SITES]

[Add to list >] [Clear list]

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

# INSTITUTIONAL CERTIFICATION

OMB Control Number: 0925-0670  
Expiration Date: November 30, 2022

Clear Form

## Rapid Acceleration for Diagnostics Program (RADx) Institutional Certification\*

For studies using data generated for the Rapid Acceleration of Diagnostics Program (RADx)

The \_\_\_\_\_ hereby assures that submission of data from the study entitled \_\_\_\_\_ to an NIH-designated data repository meets the following expectations:

- \* • The data submission is consistent, as appropriate, with applicable national, tribal, and state laws and regulations as well as relevant institutional policies.
- \* • Any limitations on the research use of the data, as expressed in the informed consent documents, are delineated in the table on page 3.
- \* • The identities of research participants will not be disclosed to NIH-designated data repositories.
- \* • An Institutional Review Board (IRB), and/or Privacy Board, and/or equivalent body, and a relevant senior-level institutional staff (e.g., Dean, Vice President/Provost for Research, Chief Science Officer) as applicable, has reviewed the investigator's proposal for data submission and assures that:
  - \* ○ The protocol for the collection of genomic and phenotypic data is consistent with 45 CFR Part 46;<sup>2</sup>
  - \* ○ Data submission and subsequent data sharing for research purposes are consistent with the informed consent of study participants from whom the data were obtained;
  - \* ○ Consideration was given to risks to individual participants and their families associated with data submitted to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results;
  - \* ○ To the extent relevant and possible, consideration was given to risks to groups or populations associated with submitting data to NIH-designated data repositories and subsequent sharing, including unrestricted access to genomic summary results; and
  - \* ○ The investigator's plan for de-identifying datasets is consistent with the HHS Regulations for the Protection of Human Subjects\*\*

\* Certification must be provided for all sites contributing samples. If more than one site is contributing samples, the primary site may submit one Institutional Certification indicating that they are providing certification on behalf of all collaborating sites. Alternatively, each site providing samples may provide its own Institutional Certification.

\*\*Investigators should de-identify human data that they submit to NIH-designated data repositories according to the standards set forth in the HHS Regulations for the Protection of Human Subjects to ensure that the identities of research subjects cannot be readily ascertained with the data. Investigators should also strip the data of identifiers according to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. The de-identified data should be assigned random, unique codes by the investigator, and the key to other study identifiers held by the submitting institution.

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

# INSTITUTIONAL CERTIFICATION

OMB Control Number: 0925-0670  
Expiration Date: November 30, 2022

Clear Form

## Rapid Acceleration for Diagnostics Program (RADx) Institutional Certification\*

For studies using data generated for the Rapid Acceleration of Diagnostics Program (RADx)

The individual-level data are to be made available through (check one)

- controlled-access<sup>3</sup>
- unrestricted access<sup>4</sup>

If unrestricted access is marked, the data use limitations table on the following page(s) does not need to be completed.

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

\* Certification must be provided for all sites contributing samples. If more than one site is contributing samples, the primary site may submit one Institutional Certification indicating that they are providing certification on behalf of all collaborating sites. Alternatively, each site providing samples may provide its own Institutional Certification.

\*\*Investigators should de-identify human data that they submit to NIH-designated data repositories according to the standards set forth in the HHS Regulations for the Protection of Human Subjects to ensure that the identities of research subjects cannot be readily ascertained with the data. Investigators should also strip the data of identifiers according to the Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule. The de-identified data should be assigned random, unique codes by the investigator, and the key to other study identifiers held by the submitting institution.

# INSTITUTIONAL CERTIFICATION

OMB Control Number: 0925-0670  
Expiration Date: November 30, 2022

**Clear Form**

## Rapid Acceleration for Diagnostics Program (RADx) Institutional Certification\*

*For studies using data generated for the Rapid Acceleration of Diagnostics Program (RADx)*

NIH expects the submitting institution(s) to select one of the three standard [Data Use Limitations](#) (DULs) for appropriate secondary use, or, if necessary, create a customized DUL. DULs are developed based on the original informed consent of the participant(s).

**Data Use Limitations**

General Research Use	GRU	Use of the data is limited only by the terms of the Data Use Certification; these data will be added to the <a href="#">dbGaP Collection</a> .
Health/Medical/Biomedical	HMB	Use of the data is limited to health/medical/biomedical purposes, does not include the study of population origins or ancestry.
Disease-specific [list disease]	DS	Use of the data must be related to the specified disease.
Other		[ENTER CUSTOMIZED TEXT, IF APPLICABLE]

Additional modifiers to the standard DULs (e.g., Not-for-profit Use Only) can be indicated, if appropriate. Use of the modifiers should have a basis in the informed consent from the participants or in special knowledge of the preferences of the original study population.

**Data Use Limitation Modifiers (Optional)**

IRB Approval Required	IRB	Requestor must provide documentation of local IRB approval.
Publication Required	PUB	Requestor agrees to make results of studies using the data available to the larger scientific community.
Collaboration Required	COL	Requestor must provide a letter of collaboration with the primary study investigator(s).
Not-for-profit Use Only	NPU	Use of the data is limited to not-for-profit organizations.
Methods	MDS	Use of the data includes methods development research (e.g., development and testing of software or algorithms).
Genetic Studies Only	GSO	Use of the data is limited to genetic studies only.

Using the tables above, please indicate in the table below the consent group(s) for each collaborating study site. Use one row per consent group.

Collaborating Site Name	Data Use Limitation	Data Use Limitation Modifiers (optional)
Eg: Cold Cohort Study	Health/Medical/Biomedical	<input type="checkbox"/> IRB <input type="checkbox"/> PUB <input type="checkbox"/> COL <input type="checkbox"/> NPU <input type="checkbox"/> MDS <input type="checkbox"/> GSO
Eg: Cold Cohort Study	Genetic Specific Research	<input type="checkbox"/> IRB <input type="checkbox"/> PUB <input type="checkbox"/> COL <input type="checkbox"/> NPU <input type="checkbox"/> MDS <input type="checkbox"/> GSO
	General Research Use	<input type="checkbox"/> IRB <input type="checkbox"/> PUB <input type="checkbox"/> COL <input type="checkbox"/> NPU <input type="checkbox"/> MDS <input type="checkbox"/> GSO
	Select consent group title	<input type="checkbox"/> IRB <input type="checkbox"/> PUB <input type="checkbox"/> COL <input type="checkbox"/> NPU <input type="checkbox"/> MDS <input type="checkbox"/> GSO
	Select consent group title	<input type="checkbox"/> IRB <input type="checkbox"/> PUB <input type="checkbox"/> COL <input type="checkbox"/> NPU <input type="checkbox"/> MDS <input type="checkbox"/> GSO
	Select consent group title	<input type="checkbox"/> IRB <input type="checkbox"/> PUB <input type="checkbox"/> COL <input type="checkbox"/> NPU <input type="checkbox"/> MDS <input type="checkbox"/> GSO

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

# DATA SUBMISSION INFORMATION

## Rapid Acceleration of Diagnostics (RADx<sup>SM</sup>) Data Sharing & Submission Information

Version 12/2020

Provide the information listed below and return to your NIH Program Officer (PO).

Checklist of required documents:

[Institutional Certifications](#)

[RADx<sup>SM</sup> Data Sharing & Submission Information](#)

### PART I – Study Registration Information

Study name:

Is this a multi-center study?

Yes     No

If YES, list participating sites:

Data will be submitted (choose one):

- By date (MM/DD/YYYY)  
 Data will be submitted by batches over Study Timeline  
(e.g. based on clinical trial enrollment benchmarks)

Specify:

Target data delivery date:  (MM/DD/YYYY) Target public release date:  (MM/DD/YYYY)

Number of gigabytes of data to be deposited:  Estimated number of study participants:

The data are to be made available through:

- RADx<sup>SM</sup> Data Hub  
 Sequence Read Archive (SRA)  
 Array Express  
 ClinVar  
 dbGaP  
 dbVar  
 dbSNP

- ENA  
 GenBank  
 GEO  
 MGI  
 Trace Archive

Unrestricted access     Controlled Access

Other (list all):

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA: WHEN/WHERE
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

# DATA SUBMISSION INFORMATION

PART IV – Study Description			
Study type(s) (e.g. collection, longitudinal, case-control, case set, control set, parent-offspring trios, cohort):			
Check all data types expected for this study:			
Species	General Data Types		
	Human Data	Behavioral	Genotyping
Non-Human Data	Clinical	Imaging	Proteomic
Sample Collection	Cognitive	Immunological	Psychological
	Existing (Legacy)	Individual Genotype	Questionnaires/Surveys
Genomic	Prospective Sample	Individual Phenotype	Social
	Aggregate Data	Individual Sequencing	Supporting Documents
Individual-level Data	Metabolomic		
Non-human Data	Metagenomic		
Other (specify):			
Phenotype			
	Aggregate Data		
Individual-level Data			
Non-human Data			
Other (specify):			
Sample Types			
	DNA	From Repository	
Name:			
Germline	Microbiome		
Mitochondria	RNA		
Single Cell	Tumor/Natural		
Other (specify):			
Genomic Data Types			
Genotype	Sequencing	Analyses	Array Data
	Array CGH CNVs	16S rRNA	Array-derived Expression
Array-derived Genotypes	Epigenomic Marks	Array-derived Methylation	Methylation Array
CNV calls derived from Sequencing	Sanger	Association/Linkage Results	SNP Array
CNV calls from microarray	Targeted Exome	RNA Seq derived Expression	Other (specify):
Genotype calls derived from Sequence	Targeted Genome	Other (specify):	
Non-human data	Targeted Transcriptome		
Somatic SNV (.MAF)	Whole Exome		
Other (specify):	Whole Genome		
	Whole Transcriptome		
	Other (specify):		

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA: WHAT
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

# DATA SUBMISSION INFORMATION

## PART V – Acknowledgement Statement(s)\*\*\*

The submitting PI should provide specific points that should be included in an acknowledgement, such as sources of support or collaborators who have made subjects or samples available. Any NIH support must be specifically acknowledged by including the grant number. Consider citing a specific publication that comprehensively describes the origin of the dataset.

The suggested Acknowledgement Statement to accompany the dataset is:

### EXAMPLE:

[ANY PROGRAM SPECIFIC LANGUAGE]. National Institutes of Health (NIH) support was provided in part by grants from [Institute or Center Name]. [Grant pr contract #]. The dataset(s) used for the analyses described in this manuscript was obtained from [NAME OF REPOSITORY] found at [https://\[XXXXX\]](https://[XXXXX]) number phs00XXXX

## PART VI – Original Summary of Study

Provide an original description of the study!

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA: WHAT
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

# DATA SUBMISSION INFORMATION

The screenshot shows the dbGaP study access page for the National Institutes of Health The Cancer Genome Atlas (TCGA). The top navigation bar includes links for Request Access, Study version history, and tabs for Study, Phenotype Datasets, Variables, Molecular Datasets, Analyses, and Documents. A sub-navigation bar below the main tabs includes Jump to: Authorized Access | Attribution | Authorized Requests. The main content area displays the study identifier phs000178.v11.p8 and its title, "Genome-Wide Analysis of Noncoding Regulatory Mutations in Cancer". A "Study Description" section provides an overview of the TCGA project, mentioning it is a comprehensive effort to accelerate our understanding of cancer through genome sequencing. It notes that TCGA is a joint effort of the National Cancer Institute (NCI) and the National Human Genome Research Institute (NHGRI), both part of the National Institutes of Health, U.S. Department of Health and Human Services. Below this, a "Substudies" section lists phs000854.v3.p8. A "Important Links and Information" box contains links to NCI Genomic Data Commons, instructions for requestors, the Data Use Certification (DUC) Agreement, and a Talking Glossary of Genetic Terms. At the bottom, a note specifies that TCGA projects are organized into two tiers: Open Access and Controlled Access. The Open Access tier contains data that cannot be attributed to an individual research participant, while the Controlled Access tier contains individual-level genotype data unique to an individual, requiring user certification through dbGaP Authorized Access.

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA: WHAT
- ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION

# DATA SUBMISSION INFORMATION

## PART VII - Consent Groups

The NIH promotes the broad and responsible sharing of research for 'general research use'. However, NIH also recognizes that in some circumstances broad sharing may not be consistent with the informed consent of the research participants whose data are included in the dataset. A data use limitation (DUL) statement is a brief written description of limitations, if any, on the distribution and use of human data submitted to controlled-access NIH designated data repositories, such as the NIH database of Genotypes and Phenotypes (dbGaP). Limitations on the data use should be described in the [Institutional Certification](#). NIH provides [Points to Consider in Developing Effective Data Use Limitations](#) that are developed based on the original informed consent from the participants.

Data contains:	
<input type="checkbox"/> Controlled Access Data <input type="checkbox"/> Public Access Data	
If your data does NOT contain Controlled Access Data, skip to Part IX.	
If your data does contain Controlled Access Data, select all relevant consent group categories:	
Consent Group Category	Data Use Limitations
<input checked="" type="checkbox"/> General Research Use	Use of the data is limited only by the terms of the Data Use Certification (DUC) <small>Requestor must provide documentation of local IRB approval</small>
<input type="checkbox"/> IRB approval required	
<input type="checkbox"/> Publication required	Requestor agrees to make results of studies using the data available to the larger scientific community
<input type="checkbox"/> Collaboration required	Requestor must provide letter of collaboration with the primary study investigator(s)
<input type="checkbox"/> Not-for-profit use only	Use of the data is limited to not-for-profit organizations
<input checked="" type="checkbox"/> Health/Medical/Biomedical	Use of the data is limited to health/medical/biomedical purposes, does not include study of population origins or ancestry
<input type="checkbox"/> IRB approval required	Requestor must provide documentation of local IRB approval
<input type="checkbox"/> Publication required	Requestor agrees to make results of studies using the data available to the larger scientific community
<input type="checkbox"/> Collaboration required	Requestor must provide letter of collaboration with the primary study investigator(s)
<input type="checkbox"/> Not-for-profit use only	Use of the data is limited to not-for-profit organizations
<input checked="" type="checkbox"/> Disease-Specific	Use of the data must be related to the specified disease
<input type="checkbox"/> IRB approval required	Requestor must provide documentation of local IRB approval
<input type="checkbox"/> Publication required	Requestor agrees to make results of studies using the data available to the larger scientific community
<input type="checkbox"/> Collaboration required	Requestor must provide letter of collaboration with the primary study investigator(s)
<input type="checkbox"/> Not-for-profit use only	Use of the data is limited to not-for-profit organizations
<input type="checkbox"/> Related conditions	Use of data includes disease XX and related conditions (Describe and include examples):  <input type="text"/>
<input type="checkbox"/> Other (describe):	<input type="text"/>

## INSTITUTIONAL CERTIFICATION

- RESEARCH PARTICIPANTS PROTECTIONS
- GENERAL RESEARCH USE (GRU)

## DATA SHARING AND SUBMISSION INFORMATION

- DATA: ACKNOWLEDGEMENT STATEMENT
- STUDY DESCRIPTION



# **FOR RADx STUDY REGISTRATION AND DATA ACCESS QUESTIONS AND ASSISTANCE**

**Vivian OTA WANG**  
**E-mail: otawang@nih.gov**



NATIONAL  
CANCER  
INSTITUTE

[www.cancer.gov](http://www.cancer.gov)

[www.cancer.gov/espanol](http://www.cancer.gov/espanol)